Teva Pharmaceutical Industries Ltd. $TEVA Stock: Phoenix Financial Ltd. Reduces Stake

Phoenix Financial Ltd. decreased its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 0.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 42,625,947 shares of the company’s stock after selling 307,420 shares during the period. Teva Pharmaceutical Industries accounts for 11.3% of Phoenix Financial Ltd.’s investment portfolio, making the stock its biggest holding. Phoenix Financial Ltd.’s holdings in Teva Pharmaceutical Industries were worth $1,688,139,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. WCM Investment Management LLC grew its position in Teva Pharmaceutical Industries by 191.4% in the 1st quarter. WCM Investment Management LLC now owns 40,820,600 shares of the company’s stock worth $1,157,264,000 after purchasing an additional 26,813,522 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. increased its holdings in shares of Teva Pharmaceutical Industries by 1.3% during the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 39,422,212 shares of the company’s stock worth $1,561,120,000 after purchasing an additional 500,000 shares during the period. Wellington Management Group LLP raised its position in shares of Teva Pharmaceutical Industries by 5.8% during the second quarter. Wellington Management Group LLP now owns 7,671,157 shares of the company’s stock valued at $259,899,000 after buying an additional 419,329 shares during the last quarter. Janus Henderson Group PLC lifted its stake in shares of Teva Pharmaceutical Industries by 1.5% in the first quarter. Janus Henderson Group PLC now owns 4,816,657 shares of the company’s stock valued at $145,076,000 after buying an additional 72,880 shares during the period. Finally, Bessemer Group Inc. lifted its stake in shares of Teva Pharmaceutical Industries by 1.6% in the first quarter. Bessemer Group Inc. now owns 4,350,483 shares of the company’s stock valued at $131,036,000 after buying an additional 70,058 shares during the period. 54.05% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CEO Richard D. Francis sold 250,000 shares of the business’s stock in a transaction on Tuesday, November 10th. The stock was sold at an average price of $42.24, for a total value of $10,560,000.00. Following the sale, the chief executive officer owned 927,529 shares of the company’s stock, valued at $39,178,824.96. The trade was a 21.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Roberto Mignone sold 367,600 shares of the company’s stock in a transaction on Friday, September 18th. The shares were sold at an average price of $39.06, for a total value of $14,358,456.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 715,945 shares of company stock worth $29,061,351 in the last 90 days. 0.54% of the stock is owned by corporate insiders.

Teva Pharmaceutical Industries Price Performance

Shares of Teva Pharmaceutical Industries stock traded up $0.87 during trading on Friday, hitting $44.52. 7,562,490 shares of the company’s stock traded hands, compared to its average volume of 6,968,955. The company has a market cap of $51.88 billion, a PE ratio of 103.53, a PEG ratio of 4.09 and a beta of 0.97. The firm’s fifty day moving average price is $40.16 and its 200 day moving average price is $35.07. Teva Pharmaceutical Industries Ltd. has a twelve month low of $24.01 and a twelve month high of $44.57. The company has a debt-to-equity ratio of 1.59, a current ratio of 0.95 and a quick ratio of 0.74.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Tuesday, November 3rd. The company reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.14. Teva Pharmaceutical Industries had a net margin of 2.94% and a return on equity of 33.20%. The firm had revenue of $4.39 billion during the quarter, compared to analyst estimates of $4.23 billion. During the same quarter in the prior year, the business posted $0.78 earnings per share. The company’s quarterly revenue was down 1.9% compared to the same quarter last year. Analysts forecast that Teva Pharmaceutical Industries Ltd. will post 1.98 earnings per share for the current year.

Key Teva Pharmaceutical Industries News

Here’s some of the latest news about TEVA:

• Positive Sentiment: Piper Sandler raised its price target to $56 from $44 and maintained an Overweight rating, pointing to potential upside. HC Wainwright also issued a positive forecast for Teva’s FY2026 earnings, though the report provided no further details. Piper Sandler analyst rating HC Wainwright forecast
• Positive Sentiment: At its R&D Day, Teva outlined a target of $6–7 billion in innovative-medicines revenue by 2030 and highlighted potential first-in-class pipeline treatments, including for Tourette syndrome, celiac disease and intestinal scarring. These are longer-term opportunities, not guaranteed results. Teva R&D Day announcement
• Negative Sentiment: CEO Richard Francis sold 250,000 shares for about $10.56 million, reducing his direct ownership by 21.23%. EVP Richard Daniell also sold shares in two reported transactions—20,003 shares on Nov. 11 and 25,000 on Nov. 9—cutting his reported stake. Insider selling can weigh on sentiment, although it does not by itself establish the executives’ view of Teva’s prospects. CEO SEC filing EVP SEC filing

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Barclays lifted their target price on Teva Pharmaceutical Industries from $42.00 to $47.00 and gave the stock an “overweight” rating in a research report on Thursday, October 15th. Oppenheimer upped their price target on Teva Pharmaceutical Industries from $50.00 to $52.00 and gave the company an “outperform” rating in a report on Friday, October 9th. HC Wainwright assumed coverage on Teva Pharmaceutical Industries in a research report on Monday, November 2nd. They issued a “buy” rating and a $52.00 price objective for the company. Piper Sandler lifted their price objective on Teva Pharmaceutical Industries from $44.00 to $56.00 and gave the stock an “overweight” rating in a report on Thursday. Finally, Weiss Ratings upgraded Teva Pharmaceutical Industries from a “hold (c)” rating to a “hold (c+)” rating in a research report on Wednesday, November 4th. Thirteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries presently has an average rating of “Moderate Buy” and a consensus price target of $48.15.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.